Riluzole use and reasons for non-use in people with amyotrophic lateral sclerosis in Aotearoa New Zealand

Key Points

• Uptake of riluzole remains low among patients with amyotrophic lateral sclerosis in New Zealand, impacting survival rates.
• Only a small percentage of people with ALS are prescribed riluzole, despite its established benefits in extending life.
• Assessment shows that prescribers often lack updated information on riluzole's risk-benefit profile, which affects prescription rates.
• The introduction of liquid riluzole could enhance accessibility for patients, potentially increasing overall uptake.